Brief: Pharming Group Doses First Patient In Phase II CVID Trial
20/03/2025 06:11
March 20 (Reuters) - Pharming Group NV PHAR.AS: DOSES FIRST PATIENT IN PHASE II CVID TRIAL PHASE II TRIAL TO INCLUDE APPROXIMATELY 20 PATIENTS AGED 12 AND OLDER TRIAL INCLUDES CVID PATIENTS WITH IMMUNE DYSREGULATION Source text: ID:nGNE9wGrvJ Further company coverage: PHAR.AS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))